Analysis Of Medication Rules And Action Mechanism Of Chinese Medicine In The Treatment Of Hashimoto’s Thyroiditis Based On Data Mining And Network Pharmacology

Objective: The TCM Inheritance Assistant Platform(2.5)was used to carry out data mining on traditional Chinese medicine prescriptions for the treatment of Hashimoto’s thyroiditis in the literature database,and the medication rules and characteristics of traditional Chinese medicine in the treatment of Hashimoto’s thyroiditis were preliminarily explored in order to better guide clinical medication and improve clinical efficacy.In addition,the therapeutic mechanism of Hashimoto’s thyroiditis in this group was explored by network pharmacology,in order to provide a scientific basis for the treatment of Hashimoto’s thyroiditis.Methods: Through using China Journal Full-text Database(CNKI),VIP database,Wanfang Data Knowledge Service Platform and China Biomedical Literature Service System as search tools and literature sources,the literature on the treatment of Hashimoto’s thyroiditis by traditional Chinese medicine from the period between the establishment of the search database and December 2022 was obtained according to the inclusion and exclusion criteria.The prescriptions and drug compositions recorded in the literature were extracted and the database was established.Data mining was performed on the internal traditional Chinese medicine(TCM)using the TCM inheritance auxiliary platform software to identify the medication rules and mine the core TCM.To investigate the mechanism of Hashimoto’s thyroiditis treated with core traditional Chinese medicine in this group combined with network pharmacology.Results: A total of 1,119 articles were collected in the literature database,and a total of236 independent prescriptions,including 290 traditional Chinese medicines,were obtained after the repetitive studies were deleted.The results of frequency analysis showed that the drugs were used for a total of 2562 times,with an average frequency of 8.83 times,among which Prunella vulgaris,Radix Astragali seu Hedysari,Fritillaria thunbergii,Rhizoma Atractylodis Macrocephalae,Radix Glycyrrhizae,Radix Bupleuri,Radix Angelicae Sinensis,and Poria were the most frequently used ones.The top five pairs of high-frequency drugs were: Prunella vulgaris–Radix Astragali(98),Fritillaria thunbergii–Prunella vulgaris(86),Rhizoma Atractylodis Macrocephalae–Poria(76),Radix Paeoniae Alba–Radix Bupleuri(72),and Rhizoma Atractylodis Macrocephalae–Radix Bupleuri(70).The new formula including Prunella vulgaris,Radix Astragali seu Hedysari,Bulbus Fritillariae Thunbergii,Poria,Rhizoma Atractylodis Macrocephalae,Radix Bupleuri,and Radix Paeoniae Alba was obtained through frequency statistics,association rule analysis,and entropy clustering analysis.A total of 50 active components and 190 corresponding drug targets,1,426 HT disease targets and 70 drug-disease intersection targets were obtained from the seven drugs of Xinfang.Screening key compounds in the network such as quercetin,kaempferol,stigmasterol and beta-sitosterol in the active ingredient-target network according to the degree value;The core targets including AKT1,CASP3,ALB,TP53 and TNF;were screened out through protein interaction network.KEGG enrichment analysis showed that the intersecting genes mainly involved t cell receptor TNF signaling pathway,IL-17 signaling pathway,EGFR tyrosine kinase inhibitor resistance,proteoglycan in cancer,MAPK signaling pathway,and PI3K-Akt signaling pathway.Conclusion: Through TCM inheritance auxiliary platform analysis,the new formula composed of Prunella vulgaris,Radix Astragali seu Hedysari,Bulbus Fritillariae Thunbergii,Poria,Rhizoma Atractylodis Macrocephalae,Radix Bupleuri,and Radix Paeoniae Alba was obtained.Analysis of network pharmacology research methods showed that the treatment of HT with the core formula mainly involved the action of active compounds such as quercetin,kaempferol,stigmasterol and β-sitosterol on core targets such as AKT1,CASP3,ALB,TP53 and TNF,and mediated TNF signaling pathway,HIF-1 signaling pathway and Erb B signaling pathway.The core combinations and new formulations summarized in this paper can provide reference for clinical medication and scientific research.However,the efficacy of the new formulation needs further clinical testing.The obtained targets and pathways are only prediction results and need to be verified in vivo and in vitro.